Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

US Capitol Capsule: Could another biosimilars fight be a brewin'?

This article was originally published in Scrip

Executive Summary

There was hardly time to yawn at the US FDA's unusually short 16 December meeting to discuss its proposed recommendations for a biosimilars user fee programme, with a handful of industry and other stakeholders getting straight to the point with their mostly anticipated comments and few questions raised by regulators at the less than two hour public event. But Christopher Ohly, a partner at the Washington law firm Schiff Hardin, predicted there's potentially a fight a brewin' based on comments made at the meeting unrelated to the user fees.


Related Companies